Supplementary Fig. 4 from A Phase 1/2 Multicenter Randomized Trial of Local Ablation Plus Toripalimab Versus Toripalimab Alone for Previously Treated Unresectable Hepatocellular Carcinoma

This is the authors' abstract. We don't add key points for this paper.

Supplementary Fig. 4 A. Progression-free survival by PD-L1 status. B. Overall survival by PD-L1 status. Dot marks indicate censored data.